
Core Viewpoint - The company intends to utilize part of its idle raised funds and idle self-owned funds for cash management, ensuring that it does not affect the normal operation of fundraising investment projects and aims to improve fund utilization efficiency and returns for shareholders [1][4][10]. Fundraising Situation - The company successfully issued 17 million shares at a price of 44.48 RMB per share, raising a total of 756.16 million RMB, with a net amount of 675.72 million RMB after deducting related issuance costs [1][2]. Fund Usage and Idle Reasons - The company has adjusted its fundraising investment projects, reallocating funds to a new project for producing 300 tons of A-40 (Atorvastatin Calcium) raw materials, with a total investment of 694.85 million RMB [2][3]. Previous Cash Management - The company approved the use of up to 100 million RMB of idle raised funds and 50 million RMB of excess raised funds for cash management, focusing on low-risk, high-liquidity financial products [3][4]. Current Cash Management Plan - The company plans to use up to 300 million RMB of idle raised funds and 300 million RMB of idle self-owned funds for cash management, with a maximum investment period of 12 months [5][6][9]. Decision Approval Process - The independent directors and the board of supervisors have reviewed and approved the cash management proposals, confirming compliance with relevant regulations and ensuring no harm to shareholder interests [8][10].